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Abstract Finding individual-level data for adequately-
powered Mendelian randomization analyses may be prob-
lematic. As publicly-available summarized data on genetic
associations with disease outcomes from large consortia
are becoming more abundant, use of published data is an
attractive analysis strategy for obtaining precise estimates
of the causal effects of risk factors on outcomes. We detail
the necessary steps for conducting Mendelian randomiza-
tion investigations using published data, and present novel
statistical methods for combining data on the associations
of multiple (correlated or uncorrelated) genetic variants
with the risk factor and outcome into a single causal effect
estimate. A two-sample analysis strategy may be em-
ployed, in which evidence on the gene-risk factor and
gene-outcome associations are taken from different data
sources. These approaches allow the efficient identification
of risk factors that are suitable targets for clinical inter-
vention from published data, although the ability to assess
the assumptions necessary for causal inference is dimin-
ished. Methods and guidance are illustrated using the ex-
ample of the causal effect of serum calcium levels on
fasting glucose concentrations. The estimated causal effect
of a 1 standard deviation (0.13 mmol/L) increase in cal-
cium levels on fasting glucose (mM) using a single lead
variant from the CASR gene region is 0.044 (95 % credible
interval -0.002, 0.100). In contrast, using our method to
account for the correlation between variants, the corre-
sponding estimate using 17 genetic variants is 0.022 (95 %
credible interval 0.009, 0.035), a more clearly positive
causal effect.
Keywords Mendelian randomization  Instrumental
variable  Causal inference  Published data  Two-sample
Mendelian randomization  Summarized data
Introduction
Mendelian randomization is a technique which uses genetic
variants to assess whether a risk factor, such as a
biomarker, has a causal effect on a disease outcome in a
non-experimental (observational) setting [1, 2]. We assume
that the chosen genetic variants are associated with the risk
factor, but not associated with any confounder of the risk
factor–outcome relationship, nor associated with the out-
come via any pathway other than that through the risk
factor of interest [3]. These three assumptions form the
definition of an instrumental variable [4]. A variant satis-
fying these assumptions divides a study population into
subgroups which are analogous to treatment arms in a
randomized controlled trial, in that they differ system-
atically with respect to the risk factor of interest, but not
with respect to confounding factors [5]. An association
between the genetic variant and the outcome therefore
implies that the risk factor has a causal effect on the
outcome.
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Mendelian randomization is a valuable approach for
identifying risk factors as potential targets for clinical or
behavioural intervention [6]. Evidence from Mendelian
randomization has been used to prioritize investigation of
certain biomarkers as causal risk factors for cardiovascular
disease: for example lipoprotein(a) [7], and interleukin-6
receptor [8]; and to de-prioritize others: fibrinogen [9],
C-reactive protein (CRP) [10], and uric acid [11]. How-
ever, it may be hard to find a suitable study population with
sufficient data on the genetic variants, and both the risk
factor and outcome of interest. As many genetic variants
only explain a small proportion of the variation in the risk
factor, large sample sizes (in some cases comprising tens of
thousands of individuals [12]) may be required for
adequately-powered Mendelian randomization investiga-
tions. Several consortia with large numbers of participants,
such as CARDIoGRAMplusC4D for coronary artery dis-
ease [13] and DIAGRAM for type 2 diabetes [14], have
published data on the association of catalogues of genetic
variants with either risk factors or disease status (a list of
consortia is given in Web Table A1). These provide precise
estimates of genetic associations which can be used to
obtain causal estimates based on Mendelian randomization
in a fast and cost-effective way. In this paper, we provide a
blueprint for this approach.
Methods
The steps involved in a Mendelian randomization investi-
gation are: (1) specification of the dataset(s) for analysis,
(2) search for candidate instrumental variables, (3)
validation of the instrumental variable assumptions, (4)
estimation of the causal effect (if appropriate), (5) sup-
plementary and sensitivity analyses. A schematic diagram
of the relevant components in a Mendelian randomization
analysis is given in Fig. 1. We proceed to outline each of
these steps.
Specification of the dataset(s) for analysis
Traditionally, Mendelian randomization analyses have
been performed on a single study or studies containing data
on genetic variants, and both the risk factor and outcome of
interest. The main advantages of using published data
rather than individual-level data are their size and scope.
The associations of these variants with the risk factor and
outcome in large consortia are likely to be more precisely
estimated than in a single study. However, it is unlikely
that published data on the genetic associations with the risk
factor, with the outcome, and with potential confounders
are available on the same set of studies.
Two-sample Mendelian randomization is a strategy in
which evidence on the associations of genetic variants with
the risk factor and with the outcome comes from non-
overlapping data sources [15]. The limiting factor for the
power of a Mendelian randomization analysis using a given
set of genetic variants is the precision in the estimate of the
genetic association with the outcome, as this association is
typically much weaker than the genetic association with the
risk factor. Published data on genetic associations with the
outcome can therefore be combined with individual-level
data from a cross-sectional study on genetic variants and
the risk factor to obtain precise Mendelian randomization
estimates. If the study used to estimate genetic associations
with the risk factor is included in the estimate of the ge-
netic association with the outcome, then this is a subsample
rather than a two-sample analysis strategy. Alternatively,
published data can be used in all aspects of the analysis. In
this case, the two published data sources may overlap (for
example, they both constitute meta-analyses and some
studies are included in both sources).
In any case, it is likely that the sets of individuals used
in the gene-risk factor and gene-outcome arms of the
analysis will not be identical. An important assumption to
ensure the validity of the analysis is that the two sets
represent samples taken from the same underlying
population. If this is not the case, then inferences may be
misleading, as the association of the genetic variants with
the risk factor may not be replicated in the set of indi-
viduals in which the association with the outcome is esti-
mated, or a variant may not be a valid instrumental variable
in both sets.
Search for candidate instrumental variables
Genetic variants are sought which are associated with the
risk factor of interest. These can be obtained from available
Fig. 1 Schematic diagram
outlining the Mendelian
randomization approach
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individual-level data or from the catalogues of genetic
variants identified by genome-wide association studies
(GWAS) that have been compiled [16]. It is important that
estimates of both the gene-risk factor and the gene-out-
come associations are available for each of these variants,
or for proxies of the variants (a proxy is a variant in
complete or near complete linkage disequilibrium with the
original variant).
In two-sample Mendelian randomization, any bias from
weak instruments (instrumental variables that are not
strongly associated with the risk factor) is in the direction
of the null [17], so the use of large numbers of genetic
variants which are valid instrumental variables should not
result in causal claims which are false positives. If the same
set of individuals is used for estimating both the gene-risk
factor and gene-outcome associations, then bias of the
causal effect estimate will be in the direction of the ob-
servational association between the risk factor and the
outcome. In subsample Mendelian randomization, or if the
data sources for the associations overlap, the net bias will
depend on the degree of overlap. If the overlap is not
substantial, then it should be in the direction of the null
[15].
Validation of the instrumental variable assumptions
The instrumental variable assumptions for a genetic vari-
ant, or set of variants, are vitally important to the validity
of any Mendelian randomization investigation. However,
the assumptions are not all empirically testable. This means
that, while the assumptions should be interrogated as far as
possible, they cannot be entirely verified and must be
justified as much by biological understanding as they are
by statistical testing.
The assumptions necessary for a genetic variant to be a
valid instrumental variable are:
1. the variant must be associated with the risk factor of
interest;
2. the variant must be independent of confounders of the
risk factor–outcome association;
3. the variant can only affect the outcome through the risk
factor—if the value of the genetic variant changes, but
not that of the risk factor, then the outcome is
unchanged [18].
With regard to biological understanding, if the function of
the gene in which the variant is located is known, this may
give a clue as to whether the variant is a plausible instru-
mental variable. For example, variants in the CRP gene are
likely to be valid instrumental variables for CRP. However,
few genetic variants discovered in GWAS investigations
are located within coding regions or have functional fol-
low-up ascribing their association to a particular gene, and
so the functional relationship between a variant and the risk
factor may not be clear.
With regard to statistical testing, the simplest and per-
haps most effective way of assessing the instrumental
variable assumptions is to test the association of the can-
didate genetic variants with a range of covariates which are
potential confounders using individual-level data. While
there is no way of testing the association of the variants
with unknown or unmeasured confounders, for several
diseases many of the covariates having the strongest as-
sociation with the outcome (and therefore the greatest po-
tential to bias causal effect estimates) are known and often
measured in epidemiological studies. Associations with
several covariates can also be assessed from the literature,
for example by searching for associations of the variants in
a GWAS catalogue [16]. However, a key advantage of
individual-level data over published data for validation is
the ability to test the associations of the candidate instru-
mental variables with a range of covariates in a systematic
way.
One difficulty with this assessment of the instrumental
variable assumptions is the problem of multiple testing. If
there are many covariates and multiple genetic variants,
then a hypothesis testing approach that accounts for the
multiple comparisons may lead to a lack of power to detect
any specific association. Additionally, as several covariates
(or the genetic variants) may be correlated, a simple
Bonferroni correction may be an over-correction. A second
difficulty is that genetic variants can be associated with a
covariate without violating the instrumental variable as-
sumptions. If, for example, a genetic variant which is a
candidate instrumental variable for body mass index (BMI)
is also associated with blood pressure levels, this may be
due to the causal effect of BMI on blood pressure and not
due to a pleiotropic effect of the variant (pleiotropy means
that a variant has multiple effects). If the genetic asso-
ciation with a covariate is entirely mediated through the
risk factor of interest, then the instrumental variable as-
sumptions are not violated. In this case, taking the example
above, the coefficient in the regression of blood pressure on
the genetic variant should be substantially attenuated on
adjustment for BMI. However, attenuation may not be
complete, due to possible measurement error in the inter-
mediate variable (here, BMI), and as the genetic variant is
not independent of blood pressure conditional on BMI due
to the presence of confounding factors between BMI and
blood pressure [3].
A practical way to proceed is to specify two sets of
genetic variants to be used as instrumental variables: a
‘conservative’ set, for which the minimum p value for the
association of each variant with a covariate is greater than a
pre-specified level (say p [ 0.01), and a ‘liberal’ set, for
which the minimum p value for each variant is greater than
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the Bonferroni corrected p value (p [ 0:05
V
where V is the
number of covariates tested). If this approach is followed,
to minimize the possibility of bias due to pleiotropy, the
Mendelian randomization estimate using the ‘conservative’
set of variants should be regarded as the primary analysis
and the estimate using the ‘liberal’ set as the secondary
analysis.
Other violations of the instrumental variable assump-
tions, such as population stratification, are more difficult to
test using only summarized data. This particular issue is
discussed in the Web Appendix in the context of the ap-
plied example.
Estimation of the causal effect
We assume that estimates and standard errors (or
equivalently estimates and p values) are available for the
genetic associations with the risk factor and with the out-
come. Initially we assume that the scenario is two-sample
Mendelian randomization and all the genetic variants
considered are uncorrelated (in linkage equilibrium). These
assumptions are later relaxed.
Genetic variants uncorrelated (linkage equilibrium)
For each of K genetic variants (k ¼ 1; . . .; K), we represent
the estimate of the genetic association with the risk factor
as Xk with standard error rXk, and the estimate of the ge-
netic association with the outcome as Yk with standard
error rYk. Usually, these genetic associations are per allele
effects: the change in the risk factor or outcome for each
additional copy of the minor (or effect) allele. If the out-
come is binary, then Yk is usually the regression coefficient
from a logistic regression, representing a log odds ratio.
Two methods have been proposed for the estimation of a
causal effect from these summarized estimates: an inverse-
variance weighted method [19], and a likelihood-based
method [20]. When the genetic associations with the risk
factor are precisely estimated, both approaches give similar
estimates. When there is considerable imprecision in the es-
timates, causal effect estimates from the inverse-variance
weighted method are over-precise, while the likelihood-based
method gives appropriately-sized confidence intervals.
The causal estimate from the inverse-variance weighted
method (b^IVW) is:
b^IVW ¼
PK
k¼1 XkYkr
2
YkPK
k¼1 X
2
kr
2
Yk
: ð1Þ
The approximate standard error of the estimate is:
seðb^IVWÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
PK
k¼1 X
2
kr
2
Yk
s
: ð2Þ
The inverse-variance weighted estimator can be motivated
as a weighted average of the ratio estimates Yk
Xk
for each
variant k, weighted using the reciprocal of an approximate
expression for their asymptotic variance
r2
Yk
X2
k
(inverse-vari-
ance weighting, as in a meta-analysis) [21]. The estimate
b^IVW expresses the causal increase in the outcome (or log
odds of the outcome for a binary outcome) per unit change
in the risk factor. The relationship between the risk factor
and the outcome is assumed to be linear.
The estimate from the likelihood-based method (b^L) is
obtained from the likelihood function of the model:
Xk Nðnk; r2XkÞ
Yk NðbLnk; r2YkÞ for k ¼ 1; . . .; K:
ð3Þ
Estimates and confidence intervals can be obtained by di-
rect maximization of the likelihood, or from Bayesian
methods. The likelihood-based method can be motivated as
finding the linear relationship between the coefficients Xk
and Yk which best fits the data, allowing for the uncertainty
in both sets of coefficients. As above, the likelihood-based
estimator expresses the causal increase in the outcome per
unit change in the risk factor assuming a linear association
between the risk factor and outcome variables.
These models assume that the data sources for the as-
sociation estimates with the risk factor and with the out-
come are non-overlapping. If they overlap, then the
coefficients Xk and Yk will be correlated in their distribu-
tions. The likelihood-based method can be modified to
accommodate this by considering a bivariate model of
ðXk; YkÞ for each genetic variant (see [20]).
Genetic variants correlated (linkage disequilibrium)
If the genetic variants are correlated, then estimates from
the inverse-variance weighted method will overstate pre-
cision. If estimates are available of the correlations be-
tween variants, then the likelihood-based method can be
modified by assuming a multivariate normal distribution
for the genetic associations with the risk factor X ¼
ðXk; k ¼ 1; . . .KÞ and with the outcome Y ¼ ðYk; k ¼ 1;
. . .KÞ, with estimates of these correlations used in the
variance–covariance matrices. The correlation between the
coefficients for the associations of two genetic variants
with the risk factor (as well as with the outcome) are equal
to the correlation between the variants themselves:
XN Kðn; RXÞ
YN KðbLn; RYÞ
ð4Þ
where the matrix component RXij ¼ rXirXjqij, with rXi
being the standard error of the coefficient Xi and qij the
S. Burgess et al.
123
correlation between variants i and j (and qii ¼ 1 for all i).
Likewise RYij ¼ rYirYjqij. Software code for implementing
these methods is provided in the Web Appendix.
Again, if the data sources for the association estimates
are overlapping then a joint normal model for the genetic
associations ðX; YÞ can be estimated:
X
Y
 
N 2K
n
bLn
 
;
RX RXY
RYX RY
  
ð5Þ
where the matrix component RXYij ¼ hrXirYjqij, with h
representing the correlation between the genetic asso-
ciations with the risk factor and outcome, and RXY ¼ RTYX .
The value of h can be estimated by bootstrapping if the
individual-level data is available; otherwise, sensitivity
analyses can be undertaken across a range of plausible
values.
Supplementary and sensitivity analyses
In addition to the primary analysis to estimate the causal
effect of the risk factor on the outcome, a number of ad-
ditional analyses can be performed, which fall into the
categories of supplementary or sensitivity analyses.
If there are multiple mechanisms by which the risk
factor may affect the outcome, and if genetic variants can
be categorized as relating to one or other of these
mechanisms, then separate Mendelian randomization esti-
mates can be obtained using each category of variants. For
example, variants may be associated with BMI by various
mechanisms, such as suppressing appetite or increasing
metabolic rate. A Mendelian randomization estimate con-
structed using variants associated with BMI through ap-
petite suppression more closely represents the causal effect
of intervening on BMI via appetite suppression. Differ-
ences in the causal estimates using genetic variants asso-
ciated with different mechanisms may be informative in
understanding the aetiology of the disease, and may high-
light specific mechanisms to prioritize for pharmacological
intervention.
If there are variants whose status as instrumental vari-
ables is uncertain, then sensitivity analyses can be per-
formed using a more conservative and a more liberal set of
genetic variants, as described in step 3. Additionally, if
there is no pleiotropy and the effects of the risk factor on
the outcome associated with changes in the genetic variants
are homogeneous for all variants, the genetic association
estimates with the risk factor and with the outcome should
follow a linear relationship passing through the origin. By
plotting the genetic association estimates with the risk
factor and with the outcome, any points which are not
compatible with a straight-line through the origin (allowing
for uncertainty in the estimates) can be investigated for
potential pleiotropy of the variants or for heterogeneity of
the causal effect (perhaps due to different mechanisms of
association with the risk factor).
A formal test for heterogeneity is known as an overiden-
tification test [22]. Examples of overidentification tests with
individual-level data include the Basmann test [23] and the
Sargan test [24]. A similar test can be derived with summa-
rized data from the likelihood-based method to test the hy-
pothesis that the causal effect bL is the same using all
variants: if bL were replaced by bLk, are the differences be-
tween the b^Lk compatible with chance? By the likelihood
ratio test, twice the difference in the log-likelihood function
evaluated at the maximum likelihood estimate with bLk ¼ bL
and evaluated at nk ¼ Xk, bLknk ¼ Yk (saturated model)
should be distributed as a chi-squared variable on K  1
degrees of freedom under the null hypothesis of homogeneity.
Example: effect of calcium levels on fasting glucose
Calcium is the most abundant mineral in the body, with a
wide range of vital functions in human biology, including
bone development and maintenance, muscle contraction,
neurotransmitter release, and exocytosis. Indeed, insulin
secretion is a calcium dependent process [25], and total
serum calcium levels have been associated with glucose
intolerance [26]. Calcium absorption is enhanced by vi-
tamin D, and vitamin D is a putative causal risk factor for
type 2 diabetes [27]. We perform a Mendelian random-
ization analysis to investigate the causal effect of serum
calcium levels on fasting glucose concentrations to illus-
trate some of the points discussed above.
For the gene-risk factor associations, we use individual-
level baseline data on 6351 subcohort participants of
European ancestry from the EPIC-InterAct study, a mul-
ticentre case-cohort study of type 2 diabetes nested within
the European Prospective Investigation into Cancer and
Nutrition (EPIC) [28]. All participants gave written in-
formed consent, and the study was approved by the local
ethics committees in the participating countries and the
Internal Review Board of the International Agency for
Research on Cancer. For the gene-outcome associations,
we use published data from the Meta-Analyses of Glucose
and Insulin-related traits Consortium (MAGIC), down-
loaded from www.magicinvestigators.org [29]. Data on per
allele genetic associations with fasting glucose are avail-
able for up to 133,010 participants without diabetes of
European ancestry from 66 studies. EPIC-InterAct par-
ticipants were not included in the MAGIC dataset, so this is
a two-sample Mendelian randomization design. Genetic
variants for both samples were available for variants on the
Cardio-Metabochip (Illumina).
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Identification of candidate variants and assessment
of instrumental variable assumptions
We compare two strategies for choosing genetic variants to
include in the Mendelian randomization analysis. The first
strategy is to include only variants from in and around the
calcium-sensing receptor (CASR) gene region [30]. This
region was shown to have the strongest association with
calcium levels in a GWAS [31] and has known biological
relevance for calcium metabolism pathways. There are 17
variants within a 500 kb range of the CASR gene in various
degrees of linkage disequilibrium; the lead variant was
rs1801725. The second strategy is to include ten variants
from the different gene regions identified as associated
with calcium levels by O’Seaghdha et al. [31]. Suitable
proxies were found for the variants which are not available
on the Cardio-Metabochip. Further details of the data and
genetic variants used in the analysis are given in Web
Tables A2 and A3.
To assess the validity of the genetic variants as instru-
mental variables, we tested the association of the variants
with a range of covariates in the EPIC-InterAct data. As-
sociations of weighted allele scores based on the two sets
of variants are displayed in Fig. 2. The weights for the
allele scores were determined from the data under analysis
by regression of calcium levels on each of variants in turn
with adjustment for age, sex and centre. The regressions of
the covariates on the allele scores were also adjusted for
age, sex and centre. The use of weights derived from the
data under analysis can lead to overfitting and weak in-
strument bias in a one-sample setting (genetic variants, risk
factor and outcome measured in the same dataset), and so
is not recommended for the primary Mendelian random-
ization analysis where it is important to mitigate against
false positive results [32].
The coefficients represent the standard deviation dif-
ference in the covariate associated with a unit increase in
the allele score [(which is scaled to be associated with a 1
standard deviation (0.13 mmol/L) increase in calcium
levels]. The allele score based on variants from the CASR
gene region does not show stronger associations with the
covariates than would be expected by chance. A search of
the literature revealed a suggestive association between
cardiac troponin-T (a regulatory protein integral to muscle
contraction) and a variant near to the CASR locus [33].
However, this association may be solely due to the genetic
effect on calcium levels, in which case the Mendelian
randomization assumptions are not violated. No other as-
sociations were reported. In contrast, the allele score based
on variants from different gene regions is associated at
p\0:01 with total cholesterol, non-high-density lipopro-
tein-cholesterol, triglycerides, apolipoprotein B, creatinine,
and uric acid, and additionally at p\0:05 with CRP. Since
summarizing a set of genetic variants as an allele score
may hide pleiotropic effects of particular variants, asso-
ciations of each of the variants individually with the co-
variates are given in Web Tables A4 and A5; this yields
similar conclusions. A discussion on potential population
stratification for variants in the CASR gene region is given
in the Web Appendix.
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Fig. 2 Associations with a range of covariates of weighted allele
scores based on genetic variants associated with calcium levels for:
(top) 17 variants in and around the CASR gene region; (bottom) 10
variants in different gene regions. Estimates are coefficients for the
difference in the covariate measured in standard deviations per unit
increase in the allele score [a unit increase in the allele score is scaled
to be associated with a 1 standard deviation (0.13 mmol/L) increase in
calcium levels]. Coefficients are obtained from the EPIC-InterAct
dataset using linear regression with adjustment for age, sex and
centre. Lines are 95 % confidence intervals
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Estimation of a causal effect
We proceed to consider causal estimation only using the
genetic variants in and around the CASR gene region.
The restriction to a single genetic region means that the
causal estimate is likely to apply only to a single
mechanism by which calcium levels affect fasting glu-
cose, and therefore may not be generalizable to other
mechanisms. However, as the genetic region has a
plausible mechanistic association with calcium levels, it
is more likely to be a valid causal estimate than one
based on variants from many genetic regions with un-
known functional relevance to calcium levels and clear
evidence of pleiotropy.
The genetic associations with calcium levels and with
fasting glucose are displayed in Fig. 3. The top panel
shows the associations for all 17 genetic variants, while
the bottom panel only shows the associations for the 6
variants associated with calcium levels at p\0:1; this
second analysis was conducted to mitigate the potential
effects of weak instrument bias. However, the data-driven
choice of instrumental variables can also lead to weak
instrument bias [34]; hence the analysis using all variants
regardless of their association with calcium levels is also
performed.
Parameters in the likelihood based model (4) were
estimated in a Bayesian framework; further details in-
cluding the vague priors used are provided in the Web
Appendix. The causal effect of calcium levels on fasting
glucose is estimated using the full set of 17 variants, the
subset of 6 variants, and the lead variant only (Table 1).
The correlations between the genetic variants were esti-
mated from the EPIC-InterAct data. The heterogeneity
test statistics are: all variants 21.5 [16 degrees of freedom
(df), p ¼ 0:15]; variants associated with calcium 3.28 (5
df, p ¼ 0:66), indicating no more heterogeneity in the
genetic associations with the risk factor and outcome
than would be expected by chance. The estimate using all
the genetic variants is more precise than the estimate
using only a subset of variants, even though the addi-
tional variants are not associated with calcium at
nominally significant levels. This example shows the
potential gain in power attained by using many genetic
variants from a single gene region.
We conclude from this example that there is evidence
that increases in calcium levels lead to increases in fasting
glucose. The lack of availability of data on important co-
variates (in particular vitamin D levels), the potential for
bias by population stratification, and the reliance on genetic
variants from a single region mean that the evidence that
intervening to lower serum calcium levels would decrease
fasting glucose concentrations is suggestive, but not
conclusive.
Discussion
In this discussion, we highlight some extensions of the
approach discussed in this paper, as well as issues in its
implementation and interpretation.
Related risk factors and pleiotropic variants
In some cases, genetic variants are associated with several
related risk factors, such as multiple lipid fractions (or
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Fig. 3 Association of genetic variants with fasting glucose (mM)
obtained from publicly-available data from MAGIC consortium
against association with calcium levels (mmol/L) obtained from
EPIC-InterAct per calcium-increasing allele for: (top) 17 variants in
and around the CASR gene region; (bottom) the subset of 6 variants in
and around the CASR gene region associated with calcium levels
(p\0:1). Lines represent 95 % confidence intervals
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several measures of the same risk factor, such as the con-
centration and particle size of lipoprotein(a)) in such a way
that it is not possible to find variants specifically associated
with each risk factor which are not associated with the
related risk factors [35]. By considering the genetic asso-
ciations with each of the risk factors in a single model, the
causal effects of each of the risk factors on the outcome can
be estimated simultaneously even from published data [36].
Such an analysis should only be attempted if the risk fac-
tors are closely biologically related and is only valid if the
pleiotropic effects of the genetic variants are restricted to
the set of risk factors under analysis.
Multiple studies and meta-analysis
If the data on the genetic associations in a Mendelian ran-
domization investigation are taken from multiple studies,
then the association estimates may represent pooled estimates
from a meta-analysis, as with the data on gene-outcome as-
sociations in the example of this paper. If the individual-level
or summarized data are available at a study level, then these
can be incorporated into the analysis using hierarchical
models, as has been previously proposed for the analysis of
individual-level data [37]. This can take into account the
heterogeneity between studies in a more principled way,
particularly if some of the studies provide information on the
genetic associations with both the risk factor and outcome.
Weight of evidence from Mendelian randomization
In a hierarchy of evidence, Mendelian randomization inves-
tigations have been advocated as providing ‘‘critical evi-
dence’’ on risk factor–outcome relationships [38]. However,
the true weight of evidence in each case depends strongly on
the plausibility of the instrumental variable assumptions for
the genetic variants. If the function of the genetic variants is
poorly understood, and there is little consistency in the causal
effect estimates from multiple variants, then a causal con-
clusion is in doubt. A non-null Mendelian randomization
estimate indicates that genetic predictors of the risk factor are
also associated with the outcome, but there may be alternative
causal pathways other than that through the risk factor of
interest. This is particularly likely if a large number of vari-
ants are included in the analysis, and/or if the justification for
using the variants in the analysis is solely on the basis of
observational associations with the risk factor. Additionally,
conclusions may still be limited by a lack of power, par-
ticularly if the genetic variants only explain a small propor-
tion of the variance in the risk factor.
Conclusion
In conclusion, we have here explained why Mendelian ran-
domization is a useful approach for the assessment of risk
factors as potential targets for clinical intervention. We have
demonstrated how published data enable efficient analysis
strategies for Mendelian randomization experiments. This is a
timely development in view of the increasing public avail-
ability of genetic association estimates in large datasets. The
efficiency of these analyses can be improved by using multiple
variants in each gene region, but correlation between the
variants must be accounted for.
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Table 1 Causal estimates for a 1 standard deviation (0.13 mmol/L) increase in calcium levels on fasting glucose (mM) using genetic variants
from in and around the CASR gene region
Number of variants F statistic Causal estimate 95 % credible interval
All variants 17 3.4 0.022 0.009, 0.035
Variants associated with calcium at p \ 0.1 6 7.9 0.028 -0.003, 0.062
Lead variant only 1 30.6 0.044 -0.002, 0.100
Estimates and 95 % credible intervals are estimated from Bayesian likelihood-based method using all 17 measured variants, using the 6 variants
associated with calcium in the EPIC-InterAct dataset (p \ 0.1), and using the lead variant (rs1801725) only. Partial F statistics are taken from the
regression of calcium on the genetic variants in a multivariable regression (with adjustment for age, sex, and centre)
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